by When InnBeauty Project – a rising star in Gen Z skincare since the brand’s launch in 2019 – decided to launch its first anti-aging product this past January, co-founders Jen Shane and Alisa Metzger knew they had to raise the introduction in a way that is sufficient to adequately make their claim. in a new category.
“We wanted to show, not tell, the consumer why our product was different,” said Metzger of Extreme Cream, which sells for $48 and aims to address fine lines and wrinkles with a formula that includes 7 percent elevated peptides, 2 percent bio- retinol and ceramides. Sold at Sephora, the product is up against more established – and generally pricier – anti-aging offerings from brands like Skinceuticals, Kiehl’s, Dr. Barbara Sturm and the like.
More from WWD
InnBeauty solution? Double down on clinical testing with a budget of $102,000 – about seven times more than any previous launch by the brand, which is projected to reach $50 million in retail sales this year – to prove the product’s claims.
“We wanted to put our product up against any other $200, $300, $500 option on the market and have the data points to show that it can perform as well,” Shane said.
So the duo upgraded the Insult Patch Repeat Test panel from the usual 50-ish panels to 200 to back up their sensitive skin-safe and hypoallergenic claims, and took advantage of confocal imaging for the first time via a VivaScope 1500 to enable consider the upper. to visibly increase skin elasticity and hydration at a cellular level. This is in addition to the brand’s standard microbial, non-comedogenic and freeze-thaw tests, as well as consumer perception studies.
Since its launch, the product has reigned as an InnBeauty top performer at Sephora — previous launches have typically been around for a month or two — and Metzger expects Extreme Cream to “continue to hold the top spot with for the long transmission,” partly due. with this increased investment in clinics, the results of which have been widely leveraged to market the product more strongly online and in Sephora stores.
“As a younger brand you have to be very tight with your budget, and clinical testing becomes quite expensive. We are happy to be able to do it at the level we want now” said Shane, adding that the brand is investing about the same amount in clinics for a “joint product,” sister Extreme Cream, launched in May.
Claims and clinical trials have always been an arms race in skin care, but as consumer demands for industry transparency increase, a cohort of brands, like InnBeauty, are becoming more prominent — in both methodology and marketing — when it comes to clinics .
“[Clinical testing] is becoming this ‘checkpoint,’ so to speak, among results-oriented consumers who want to see brands that have backup and validation for the claims they’re making,” said the cosmetic chemist and founder of BeautyStat Ron Robinson.
The case for clear and accurate claims goes beyond brownie points, however, as evidenced by a growing crop of class action lawsuits against brands like Grande Cosmetics and Nutrafol, both of which the plaintiffs consider to be are misleading marketing tactics.
Although the brand has not admitted any wrongdoing, Grande Cosmetics agreed in January to pay $6.25 million to settle a lawsuit claiming the brand did not disclose the presence of isopropyl cloprostenate – which can have harmful effects – in its products. Meanwhile, Nutrafol is facing multiple class-action lawsuits — including two filed last May and June in New York, respectively — alleging discrepancies in tests the brand’s clinical in terms of panel diversity and labeling the root cause of hair loss. supplements as “clinically proven” deceptive.
Although certain parameters of what clinical testing should look like are fairly widely agreed upon — panels of at least 30 people; trials conducted by independent third-party laboratories — much else about the process remains laissez-faire, including panel diversity commensurate with the diversity of the general public, which would ideally be table commitments at the point this, and even the context in which the word “clinical” is used and marketed.
Without any kind of government-regulated standard practice for clinical testing, “the onus is on brands to substantiate their claims,” said Ronie Schmelz, a partner at K&L Gates, who insists that’s not the same as drug claims, which there is a need to demonstrate and demand safety. the effectiveness cannot be discussed, “The FDA does not want – or need not – be involved in how cosmetic companies should go about substantiating those claims.”
However, getting the industry on the same page regarding accurate and separate labeling of consumer perception study claims (which are subjective) versus clinical claims (which are graded by experts and therefore objective). messages.
“It’s a one-two punch; there are certain claims that you should make sure you measure clinically if you’re going to do it,” said Jennifer Stansbury, co-founder of The Benchmarking Company, adding that because consumer perception studies tend to collect higher percentages and so that may be more persuasive (ie “95 percent of consumers agree…”), a brand can “always lead with the highest [consumer perception] number, followed by the clinical claim that it supports that moisture, or whatever it may be, is actually happening.”
Clinique, whose status as a dermatologist-led brand was a differentiator when it was founded in 1968 long before the emergence of dermatologist-led brands, is today thinking about how to honor its legacy while continuously evolving its approach.
That purpose has led the brand to regularly carry out new clinical trials among the existing variations in order to meet evolving consumer needs – for example, thinking that its Various Moisture Lotion is Drama launched in 1968 safe to use after intensive pulsed light therapy (IPL). in a two-week clinical trial.
“That’s a product that’s been around for a long time, and yet it has one of the most modern claims you could ask for,” said Christie Sclater, senior vice president of global product marketing, insights and analytics and education. omnichannel at Clinique. “We see the growth of aesthetic procedures, and this aspect is how we will continue to modernize the narrative for our consumers through new test demands that will benefit from it.”
Part of that also means demonstrating how Clinque’s topical offerings can measure up to certain skin-nourishing aesthetic treatments. At the American Academy of Dermatology conference in California last month, the brand revealed to attendees a recent clinical trial of its Smart Clinical Repair Wrinkle Correcting Serum, $76, showed that women who used the serum twice a day showed for 16 weeks “same improvement” “overall appearance of fine lines and wrinkles” as another group that underwent only Deka dot SmartSkin CO2 laser treatment.
The brand is also now trying to bring a clinical approach to its makeup portfolio, introducing its “Eye Safety Promise” alongside the launch of its High-fi Mascara in New York last August. In partnership with the brand’s first guiding ophthalmologist, Dr. Ashley Brissette, all of Clinique’s eye makeup products are now ophthalmologist tested and deemed safe for sensitive eyes and contact lens wearers.
“We’ve barely started calling in eye safety, and we’ll be picking up the volume a little bit,” Sclater said.
A very different clinical test, but in a similar unconventional way, informed the genesis of the beauty Exponent Beauty Liz Whitman, founded in 2019 and which has dose-out product systems, each composed of a powdered active (retinol, vitamin C and the like). and its hydrator counterpart, which aim, mixed together, to create a potent serum.
In developing her first Brightening Boost Vitamin C Power Serum, $98 for 30 doses, Whitman sent “popular vitamin C products to [Essex Testing Clinic in New Jersey] and asked them to test the concentration of the actives every day from Day One to Day 60 while opening it every day—basically mimicking a consumer using the serum dropper bottle at home,” Whitman said.
Lab result: Most products lose up to half their potency during that period, so Whitman aims to combat potency degradation with an activation serum that packs a punch for 30, 45, or whatever multiple doses that a consumer chooses to buy. .
“Consumers shouldn’t have to be investigative journalists,” Whitman said. “It’s not an apples-to-apples comparison across brands, but we need to create credible ways for consumers to understand the performance of their products.”
The best of WWD
